Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 18/20 | 0.65 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.58 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.58 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.58 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.58 |
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11895421 | 1.00 | LPAR1 (0.65) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL1246498 | 0.90 | LPAR1 (0.61) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL1246499 | 0.90 | LPAR1 (0.61) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL11895828 | 0.88 | LPAR1 (0.59) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL11895826 | 0.88 | LPAR1 (0.59) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL11896026 | 0.88 | LPAR1 (0.59) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL343879 | 0.87 | LPAR1 (0.77) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL343880 | 0.87 | LPAR1 (0.77) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL9939487 | 0.87 | LPAR1 (0.75) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL9939485 | 0.87 | LPAR1 (0.75) | LPAR1ABCC3ABCC4ABCB11CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462128-B1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2016-09-21 | — | — | EP | claimed |
| US-8592402-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2013-11-26 | — | — | US | claimed |
| US-20120196839-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. (US) | 2012-08-02 | — | — | US | claimed |
| EP-2462128-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | Amira Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| WO-2011017350-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196839-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885ABCC3 3151/4885ABCC4 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.